P1524 - GLP-1 RAs Use is Associated with Lower Mortality and Improvement of Cardiovascular Outcomes in Patients with Celiac Disease and Obesity: A Multi-Center Analysis

Donghyun Ko, MD¹, Do Han Kim, MD², Sharon Narvaez, MD³, Olanrewaju Adeniran, MBBS⁴, Luis Nieto, MD⁵, Miguel Salazar, MD⁶, Pedro Palacios-Argueta, MD⁷, Paul Kroner, MD, MSc⁸, Frank J. Lukens, MD^9
1Yale-New Haven Health/Bridgeport Hospital, Bridgeport, CT; ²Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, NY; ³Universidad de Guayaquil, School of Medicine, Atlanta, GA; ⁴West Virginia University School of Medicine, Morgantown, WV; ⁵Emory School of Medicine, Atlanta, GA; ⁶University of California Riverside, Riverside, CA; ⁷Mayo Clinic Florida, Jacksonville, FL; ⁸Riverside Regional Medical Center, Newport News, VA; ⁹Mayo Clinic, Jacksonville, FL

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are drugs that are widely studied due to its weight loss and anti-inflammatory effects. Thus, promising effects are expected in patients with inflammatory diseases such as celiac disease and obesity. The aim of our study is to determine if the use of GLP-1RAs is beneficial in decreasing mortality and cardiovascular outcomes in patients with both conditions.

Methods: A retrospective cohort study was performed using large population-based data from the TriNetX platform. Patients with celiac disease and obesity who have received GLP-1 RAs between January 1, 2010, and December 31, 2023, were identified. This group was matched with patients who did not receive GLP-RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching. The primary outcome was all-cause mortality, and secondary outcomes were cardiovascular outcomes such as heart failure, acute myocardial infarction, cerebrovascular disease, coronary revascularization, and primary hypertension.

Results: A total of 18,513 adult patients with celiac disease and obesity were identified, 2,631 of these individuals were taking GLP-1RAs; 2,333 out of 2,631 (mean [SD] age, 49.6 [13.6] years; 1,709 [73.3%] female) were matched with 2,333 individuals (mean [SD] age, 49.6 [16.3] years; 1,731 [74.2%] female) who did not take GLP-1RAs. The GLP-1RAs group had significantly lower mortality (Odds Ratio [OR], 0.34; 95% Confidence Interval [CI], 0.26-0.46), acute myocardial infarction (OR, 0.47; 95% CI, 0.30-0.73), cerebrovascular disease (OR, 0.66; 95% CI, 0.45-0.95), and primary hypertension (OR, 0.54; 95% CI, 0.41-0.71). No significant reduction in heart failure (OR, 0.78; 95% CI, 0.58-1.05) was observed. No patients from our study underwent coronary revascularization.

Discussion: Throughout our study, lower mortality was observed in GLP-1RAs users with celiac disease and obesity. Furthermore, inflammatory heart conditions such as myocardial infarction, cerebrovascular disease, and hypertension were also associated with significant improvement. Further studies could determine the exact mechanism in which inflammatory responses are modulated through this drug.


Disclosures:


Donghyun Ko, MD¹, Do Han Kim, MD², Sharon Narvaez, MD³, Olanrewaju Adeniran, MBBS⁴, Luis Nieto, MD⁵, Miguel Salazar, MD⁶, Pedro Palacios-Argueta, MD⁷, Paul Kroner, MD, MSc⁸, Frank J. Lukens, MD⁹. P1524 - GLP-1 RAs Use is Associated with Lower Mortality and Improvement of Cardiovascular Outcomes in Patients with Celiac Disease and Obesity: A Multi-Center Analysis, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.